Lixisenatide Side Effects: What Studies Report

Lixisenatide is a short-acting glucagon-like peptide-1 (GLP-1) receptor agonist that has been evaluated in randomised controlled trials in type 2 diabetes and, more recently, in early Parkinson's disease. This page collects what the published literature reported about its adverse-event and tolerability profile, and where class-level evidence from other GLP-1 receptor agonists was used as context by reviewers. It does not describe protocols, regimens or personal use.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, medication or symptom.

What the Lixisenatide Safety Literature Covers

Two randomised trials dominate the compound-specific record. The ELIXA trial randomised 6068 patients with type 2 diabetes and a recent acute coronary syndrome to lixisenatide or placebo and reported that the primary composite endpoint of cardiovascular death, myocardial infarction, stroke or hospitalisation for unstable angina occurred in 13.4% of the lixisenatide group and 13.2% of the placebo group (hazard ratio 1.02) (https://pubmed.ncbi.nlm.nih.gov/26630143/). Separately, a 2024 trial of lixisenatide in early Parkinson's disease reported motor-score differences at 12 months alongside a high frequency of gastrointestinal complaints in the active arm (https://pubmed.ncbi.nlm.nih.gov/38598572/).

Beyond those trials, most of what is written about lixisenatide tolerability appears inside class-level meta-analyses and reviews of GLP-1 receptor agonists, including pooled cardiovascular outcome trial analyses (https://pubmed.ncbi.nlm.nih.gov/31422062/) and head-to-head comparisons of individual agents (https://pubmed.ncbi.nlm.nih.gov/33767808/).

Gastrointestinal Events: What Studies Report

Gastrointestinal complaints are the most consistently reported adverse events across the GLP-1 receptor agonist literature. In the 2024 trial of lixisenatide in early Parkinson's disease, researchers reported nausea in 46% of participants who received lixisenatide and vomiting in 13% (https://pubmed.ncbi.nlm.nih.gov/38598572/). That figure comes from a population without diabetes and should not be read as a general incidence estimate; it reflects what the study observed in its own participants.

A 2022 disproportionality analysis of reports submitted to the United States FDA Adverse Event Reporting System examined gastrointestinal adverse reactions linked to individual GLP-1 receptor agonists and reported that signal patterns for events such as nausea, vomiting, diarrhoea and constipation differed between agents in the class (https://pubmed.ncbi.nlm.nih.gov/36568085/). Researchers of that analysis noted the well-known limitations of spontaneous reporting databases: reports are voluntary, denominators are unknown, and a signal is not a measure of incidence or proof of causation.

A 2021 review of head-to-head clinical studies of GLP-1 receptor agonists reported that gastrointestinal adverse events were the most common tolerability problem across the comparisons it examined (https://pubmed.ncbi.nlm.nih.gov/33767808/). An earlier review of individualised GLP-1 receptor agonist treatment in type 2 diabetes described short-acting and long-acting agents as differing in their pharmacology and in their effects on fasting versus postprandial glucose, and listed nausea and vomiting among the class-associated effects (https://pubmed.ncbi.nlm.nih.gov/22945360/).

For contrast, an evidence review of the semaglutide STEP weight-management programme reported that gastrointestinal events — nausea, diarrhoea, vomiting and constipation — were the most frequently recorded adverse events in those trials and were generally transient and mild to moderate (https://pubmed.ncbi.nlm.nih.gov/36691309/). Semaglutide is a different molecule with a different dosing profile, and findings from that programme were not lixisenatide findings.

Hypoglycemia and Pancreatic Events: What Studies Report

The ELIXA investigators reported that rates of severe hypoglycemia, pancreatitis, pancreatic neoplasms and allergic reactions were similar in the lixisenatide and placebo groups over the trial's follow-up (https://pubmed.ncbi.nlm.nih.gov/26630143/). The study also reported no significant difference in hospitalisation for heart failure or in death from any cause between groups (https://pubmed.ncbi.nlm.nih.gov/26630143/).

A 2019 systematic review and meta-analysis of cardiovascular outcome trials of GLP-1 receptor agonists in type 2 diabetes reached a similar class-level conclusion on these endpoints, reporting no increase in severe hypoglycemia, pancreatitis or pancreatic cancer compared with placebo across the pooled trials (https://pubmed.ncbi.nlm.nih.gov/31422062/). Trial populations in that analysis were people with type 2 diabetes, many at elevated cardiovascular risk, so the estimates describe that setting rather than healthy populations.

Cardiovascular and Mortality Signals: What Studies Report

Lixisenatide is one of the agents whose cardiovascular outcome data fed into class meta-analyses. The 2019 pooled analysis reported reductions in major adverse cardiovascular events, cardiovascular death, all-cause mortality, hospital admission for heart failure and composite kidney outcomes with GLP-1 receptor agonists versus placebo in patients with type 2 diabetes (https://pubmed.ncbi.nlm.nih.gov/31422062/). A 2018 meta-analysis of cardiovascular outcome trials, which included ELIXA among its constituent studies, also reported a class-level reduction in major adverse cardiovascular events relative to placebo (https://pubmed.ncbi.nlm.nih.gov/29221659/).

A 2025 systematic review and meta-analysis published in the Journal of the American College of Cardiology pooled 99,599 patients and reported both cardiovascular effects and tolerability outcomes for GLP-1 receptor agonists, with reductions in major adverse cardiovascular events accompanied by adverse-event data across the included trials (https://pubmed.ncbi.nlm.nih.gov/40892610/). It is worth noting that ELIXA itself was a neutral trial on its primary endpoint: researchers reported non-inferiority to placebo rather than superiority (https://pubmed.ncbi.nlm.nih.gov/26630143/), and class averages do not transfer automatically to any single molecule.

Skin and Injection-Site Reactions: What Studies Report

A 2024 review of the published literature on rare cutaneous adverse reactions associated with GLP-1 agonists collected case reports and case series describing skin reactions attributed to agents in this class, and researchers reported that such events were uncommon relative to gastrointestinal effects and were documented largely through individual reports rather than controlled trials (https://pubmed.ncbi.nlm.nih.gov/38795152/). Case-report evidence cannot establish incidence or causation. In ELIXA, the investigators reported that allergic reaction rates did not differ significantly between lixisenatide and placebo (https://pubmed.ncbi.nlm.nih.gov/26630143/).

Findings Outside Diabetes: What Studies Report

The 2024 randomised trial of lixisenatide in early Parkinson's disease reported a difference in motor progression scores between the lixisenatide and placebo groups at 12 months, and reported gastrointestinal adverse events — most commonly nausea, in 46% of the lixisenatide group — as the principal tolerability finding (https://pubmed.ncbi.nlm.nih.gov/38598572/). A 2025 German-language review examined GLP-1 receptor agonists as a possible pharmacological option in psychiatric illnesses and reported that the available evidence for such indications remained preliminary (https://pubmed.ncbi.nlm.nih.gov/40042613/). Both examples illustrate that adverse-event frequencies observed in one population may not match those seen in another.

Pregnancy and Reproductive Data: What Studies Report

A 2025 review of GLP-1 receptor agonist use in pregnancy reported that human safety data in pregnancy were limited, that much of the available human information came from unintended exposures around conception, and that animal reproductive findings informed much of the existing guidance (https://pubmed.ncbi.nlm.nih.gov/39181497/). The review's authors described this as an evidence gap rather than a demonstration of safety (https://pubmed.ncbi.nlm.nih.gov/39181497/).

Where the Evidence Is Absent

Several questions that readers encounter about lixisenatide are not answered in the verified literature summarised here:

• Healthy, non-diabetic adults without a neurological indication. The randomised safety data available describe type 2 diabetes after acute coronary syndrome (https://pubmed.ncbi.nlm.nih.gov/26630143/) and early Parkinson's disease (https://pubmed.ncbi.nlm.nih.gov/38598572/); other populations were not the subject of these trials.
• Long-term use beyond trial follow-up. Pooled cardiovascular outcome trial analyses reported findings over trial durations, not over decades (https://pubmed.ncbi.nlm.nih.gov/31422062/).
• Pregnancy and lactation. A 2025 review reported that human data remained limited (https://pubmed.ncbi.nlm.nih.gov/39181497/).
• Incidence estimates for rare skin events. The 2024 cutaneous review reported case-level documentation only (https://pubmed.ncbi.nlm.nih.gov/38795152/).

Comparisons Across the Class

How to Read These Findings

Three limitations recur across this evidence base. First, class meta-analyses blend agents with different half-lives and dosing schedules, and a 2012 review already described short-acting and long-acting GLP-1 receptor agonists as pharmacologically distinct (https://pubmed.ncbi.nlm.nih.gov/22945360/). Second, adverse-event percentages depend heavily on the population studied, as the difference between a post-acute-coronary-syndrome diabetes cohort (https://pubmed.ncbi.nlm.nih.gov/26630143/) and a Parkinson's disease cohort (https://pubmed.ncbi.nlm.nih.gov/38598572/) illustrates. Third, pharmacovigilance signals describe reporting behaviour rather than risk, a point researchers made explicitly in the 2022 FDA database analysis (https://pubmed.ncbi.nlm.nih.gov/36568085/). Questions about individual suitability, monitoring or interactions belong with a licensed clinician.

References

• Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome (The New England Journal of Medicine, 2015)
• Trial of Lixisenatide in Early Parkinson's Disease (The New England Journal of Medicine, 2024)
• Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials (The Lancet Diabetes & Endocrinology, 2019)
• Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis (The Lancet Diabetes & Endocrinology, 2018)
• Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients (Journal of the American College of Cardiology, 2025)
• Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database (Frontiers in Endocrinology, 2022)
• GLP-1 receptor agonists: an updated review of head-to-head clinical studies (Therapeutic Advances in Endocrinology and Metabolism, 2021)
• GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus (Nature Reviews Endocrinology, 2012)
• Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature (Archives of Dermatological Research, 2024)
• Glucagon-like peptide-1 receptor agonist use in pregnancy: a review (American Journal of Obstetrics and Gynecology, 2025)
• Efficacy and safety of semaglutide for weight management: evidence from the STEP program (Postgraduate Medicine, 2022)
• Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses? (Der Nervenarzt, 2025)